Your browser doesn't support javascript.
loading
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson, Rodney; Diacon, Andreas H; Everitt, Daniel; van Niekerk, Christo; Donald, Peter R; Burger, Divan A; Schall, Robert; Spigelman, Melvin; Conradie, Almari; Eisenach, Kathleen; Venter, Amour; Ive, Prudence; Page-Shipp, Liesl; Variava, Ebrahim; Reither, Klaus; Ntinginya, Nyanda E; Pym, Alexander; von Groote-Bidlingmaier, Florian; Mendel, Carl M.
Affiliation
  • Dawson R; Division of Pulmonology and Department of Medicine, University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa.
  • Diacon AH; Division of Physiology, Department of Medical Biochemistry, Stellenbosch University, Tygerberg, South Africa; TASK Applied Science, Bellville, South Africa.
  • Everitt D; Global Alliance for TB Drug Development, New York, NY, USA. Electronic address: dan.everitt@tballiance.org.
  • van Niekerk C; Global Alliance for TB Drug Development, Pretoria, South Africa.
  • Donald PR; Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
  • Burger DA; Department of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa; Quintiles Biostatistics, Bloemfontein, South Africa.
  • Schall R; Department of Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa; Quintiles Biostatistics, Bloemfontein, South Africa.
  • Spigelman M; Global Alliance for TB Drug Development, New York, NY, USA.
  • Conradie A; Global Alliance for TB Drug Development, Pretoria, South Africa.
  • Eisenach K; Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Venter A; MRC Centre for Tuberculosis Research, Stellenbosch University, Tygerberg, South Africa; Task Applied Science, Tygerberg, South Africa.
  • Ive P; Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Page-Shipp L; Aurum Institute, Parktown, Johannesburg, South Africa.
  • Variava E; Klerksdorp Tshepong Hospital Complex, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Reither K; Swiss Tropical and Public Health Institute, Basel, Switzerland; Ifakara Health Institute, Bagamoyo, Tanzania.
  • Ntinginya NE; NIMR-Mbeya Medical Research Centre, Mbeya, Tanzania.
  • Pym A; KwaZulu-Natal Research Institute for Tuberculosis & HIV, Nelson R Mandela School of Medicine, Durban, South Africa.
  • von Groote-Bidlingmaier F; TASK Applied Science, Bellville, South Africa.
  • Mendel CM; Global Alliance for TB Drug Development, New York, NY, USA.
Lancet ; 385(9979): 1738-1747, 2015 May 02.
Article in En | MEDLINE | ID: mdl-25795076
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazinamide / Tuberculosis, Pulmonary / Tuberculosis, Multidrug-Resistant / Fluoroquinolones / Nitroimidazoles / Antitubercular Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Lancet Year: 2015 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazinamide / Tuberculosis, Pulmonary / Tuberculosis, Multidrug-Resistant / Fluoroquinolones / Nitroimidazoles / Antitubercular Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Lancet Year: 2015 Document type: Article Affiliation country: